FALLOPIAN TUBE CANCER

This study tests whether adding a targeted drug (olaparib) to heated chemotherapy given during surgery can safely treat advanced ovarian cancer. About 55 adults with stage III ovarian cancer will take olaparib pills before and after surgery. The goal is to find the best dose and …

This study tests an experimental drug called IMGN151 for people with gynecologic cancers, including ovarian cancer. The drug is given alone or with other cancer treatments to see if it is safe and works. About 377 adults will take part at sites worldwide. The goal is to find bett…

This study looks at whether women with advanced ovarian cancer who have had all visible tumor removed can safely receive only 3 cycles of chemotherapy instead of the usual 6, followed by the maintenance drug niraparib. The goal is to see if the shorter chemo course is just as eff…

This study tests a drug called TORL-1-23 in 230 women with advanced ovarian, fallopian tube, or peritoneal cancer that no longer responds to platinum chemotherapy and has a specific marker (claudin 6). The goal is to see if the drug can shrink tumors and how safe it is. Participa…

This study tests if removing lymph nodes near the liver (hepato-celiac lymphadenectomy) can help control advanced or recurrent ovarian cancer. About 94 women with stage III/IV or platinum-sensitive recurrent ovarian cancer will receive this surgery. Researchers will track how man…

This study tests whether adding a second drug (bevacizumab) to standard niraparib treatment helps keep advanced ovarian cancer from coming back longer. About 970 women with newly diagnosed advanced ovarian, fallopian tube, or peritoneal cancer will take part. The main goal is to …

This study tests whether a new drug combination (sacituzumab tirumotecan with or without bevacizumab) can help people with platinum-sensitive recurrent ovarian cancer live longer without their cancer getting worse. About 770 adults whose cancer responded to second-line chemothera…

This early-stage study tests an experimental treatment called 27T51, a type of immune cell therapy (CAR T) designed to target a protein called MUC16 found on certain cancer cells. The study involves about 90 women with ovarian, peritoneal, or fallopian tube cancer that has come b…

This study tests a new drug called BL-B01D1 against standard chemotherapy in 384 adults with ovarian, fallopian tube, or primary peritoneal cancer that has become resistant to platinum-based treatment. The goal is to see if BL-B01D1 can slow cancer growth and improve survival. Pa…

This study tests a technique called acute normovolemic hemodilution (ANH) during ovarian cancer surgery. ANH involves removing some blood before surgery and replacing it with fluids, then giving the blood back later. The goal is to see if this reduces the need for donor blood tra…

This study tests a drug called relacorilant combined with other treatments for people with ovarian, fallopian tube, peritoneal, or endometrial cancers. About 270 participants will receive the drug combination to see if it slows cancer growth. The goal is to find better options fo…

This study tests whether combining two drugs, mirvetuximab soravtansine and olaparib, can effectively control recurrent ovarian, peritoneal, or fallopian tube cancer after initial treatment. About 53 women whose cancer responded to platinum-based chemotherapy will receive the dru…

This early-stage study tests a new drug called azenosertib (ZN-c3) combined with standard chemotherapy or bevacizumab in people with ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum-based treatment. The goal is to find safe doses and see if th…

This study tests a drug called Rina-S in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to check safety and see if the drug shrinks tumors. About 764 participants with cancers like ovarian, lung, breast, or endometrial cancer will t…

This early-phase study tests a new drug called XMT-1660 in people with advanced solid tumors, including triple-negative breast, ovarian, and endometrial cancers. The main goals are to find a safe dose and check for side effects. About 319 participants will receive the drug to see…

This early-phase study is testing whether combining two drugs, Cirtuvivint and Olaparib, is safe for people with ovarian cancer that no longer responds to platinum chemotherapy. About 50 women with specific genetic markers (BRCA/HRD) will take the pills at different schedules. Th…

This study tests an experimental drug called ART0380, taken as a pill, for people with advanced or metastatic solid tumors (cancers that have spread). The goal is to find a safe dose and see if it works alone or with standard chemotherapies (gemcitabine or irinotecan). About 442 …

This study tests whether two drugs, senaparib and temozolomide, can shrink tumors in people with a certain type of ovarian cancer that has an ARID1A gene change. About 18 adults with recurrent or persistent clear cell or endometrioid ovarian, fallopian tube, or primary peritoneal…

This study tests whether adding an experimental drug (IMNN-001) to standard chemotherapy and bevacizumab can better eliminate tiny leftover cancer in people with newly diagnosed advanced ovarian, fallopian tube, or peritoneal cancer. About 30 participants will be randomly assigne…

This early-phase study is testing whether adding aspirin to standard chemotherapy can help the immune system fight ovarian, fallopian tube, or peritoneal cancer more effectively. About 100 women will receive aspirin alongside their chemo before surgery. Researchers will measure c…

This study tests an investigational drug called REGN5668, alone or combined with other drugs, in people with ovarian, fallopian tube, primary peritoneal, or endometrial cancers. The goal is to find the safest dose and see if the treatment can shrink tumors. About 612 participants…

This phase 3 trial tests whether adding the experimental drug IMNN-001 to standard chemotherapy helps people with advanced ovarian, fallopian tube, or primary peritoneal cancer live longer. About 500 newly diagnosed adults will receive either the drug combination or chemotherapy …

This study tests whether adding mirvetuximab soravtansine to standard bevacizumab maintenance therapy can delay cancer return in women with a specific type of recurrent ovarian, fallopian tube, or peritoneal cancer. About 520 adults whose cancer has a high level of a protein call…

This study tests whether adding a vitamin A-like drug (ATRA) to a platelet-boosting medication (romiplostim N01) works better than the platelet drug alone for cancer survivors whose platelet counts stay low after chemotherapy. About 220 adults with gynecologic, breast, or lung ca…

This study tests whether a cancer-killing virus (Olvi-Vec) given into the abdomen can make platinum-resistant ovarian cancer respond to chemotherapy again. About 186 women whose cancer has not responded to at least three prior treatments will receive either Olvi-Vec plus chemo an…

This study tests a new drug combination (carboplatin plus mirvetuximab soravtansine) given before surgery to people with advanced ovarian, fallopian tube, or peritoneal cancer that has a specific protein (FRα). The goal is to see if the treatment shrinks tumors enough to improve …

This study tests a new oral drug, AVZO-021, in people with advanced solid tumors that have not responded to other treatments. The drug targets a protein called CDK2 to slow or stop cancer growth. The trial has two phases: first to find the safest dose, then to see if it shrinks t…

This study tests an experimental drug called ubamatamab, alone or with other cancer drugs, in people with advanced ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see how safe and effective these combinations are. About 220 participants w…

This study looks at a new approach to prevent ovarian cancer in women with BRCA or other high-risk gene mutations. Instead of removing both ovaries and fallopian tubes at once, participants first have only the fallopian tubes removed, delaying ovary removal until later. The goal …

This study tests whether a combination of two drugs (propranolol and etodolac) plus mind-body training and music therapy can reduce stress in women with advanced ovarian cancer undergoing surgery. About 35 participants will be randomly assigned to receive this bundle or standard …

This study looks at how the antifungal drug itraconazole changes the way the body processes a cancer drug called AZ14170132, which is part of a targeted therapy for ovarian, peritoneal, and fallopian tube cancers. About 24 people with these cancers will take both drugs in a fixed…

This early study is testing a small implantable device that sits inside a tumor and measures how different chemotherapy drugs work against ovarian, fallopian tube, and peritoneal cancers. About 20 people with advanced cancer will have the device placed and removed during standard…

This study follows 1,000 women with newly diagnosed ovarian, fallopian tube, or primary peritoneal cancer to see how their genetic makeup (BRCA and HRD status) influences their response to standard treatments. Participants receive usual care, and researchers collect data on surge…